Farxiga Approved in the US for the Treatment of Chronic Kidney Disease in Patients at Risk of Progression With and Without Type-2 Diabetes
30 April 2021
Approval is the most significant advancement in the treatment of chronic kidney disease in more than 20 years
In DAPA-CKD Phase III trial, Farxiga demonstrated unprecedented reduction in the risk of the composite of worsening of...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Chronic Kidney Disease | Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Urology & Nephrology